A comparative assessment of 5 immunoassays for SARS-CoV-2 showed that these assays achieved sensitivity and specificity of at least 98%.
While the COVID-19 pandemic is a stress-inducing event, published empirical studies about mental health consequences are rare.
Investigators conducted a single-center study to evaluate the anti-SARS-CoV-2 antibodies at baseline and 60 days in health care personnel, who are at particular risk if antibodies level decline.
Pneumomediastinum, although a rare phenomenon, is more prevalent in patients with COVID-19 compared with historical patients with adult respiratory distress syndrome.
An interim analysis of the phase 2 study evaluated the combination therapy in recently diagnosed patients with mild to moderate COVID-19.
Patients with severe COVID-19 pneumonia had improved prognosis after receiving a short course of methyl-prednisolone pulses during the second week of disease.
The antibody solution is derived from plasma donated by healthy individuals who have recovered from COVID-19.
The second part of the study will assess the efficacy and safety of a single intravenous infusion of VIR-7831 in approximately 1300 patients.
Although hospitalization risk was higher, mortality, thrombosis, and ICU admission risks were the same in patients with and without liver transplants.
Remdesivir was immediately discontinued in both patients and a continuous infusion of acetylcysteine was initiated.